Funding Received
$58.5 Million in 5 Rounds from 3 Investors
Most Recent Funding
$43 Million on January 4, 2013 / Undisclosed Round
Headquarters:
Alpharetta, GA
Description:
EndoChoice, a platform-technology firm, provides devices, diagnostics and infection control for treating gastrointestinal diseases.
Categories:
Biotechnology, Health Care
Website:
http://www.endochoice.com

Company Details

Update

Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

Past Team (1)

Update

Funding Rounds (5) - $43M

Update

Board Members and Advisors (3)

Update

Investors (3)

Update

Offices/Locations (1)

Update
  • Office

    11810 Wills Rd.

    Alpharetta, GA 30009

    USA

Images (1)

Update
  • D19e2494279ed5260fc8acc39445e0a2